Literature DB >> 11979341

Small-sized low-density lipoproteins of subclass B from patients with end-stage renal disease effectively augment tumor necrosis factor-alpha-induced adhesive properties in human endothelial cells.

Andreas Ambrosch1, Regina Müller, Claudia Freytag, Stefan Borgmann, Jürgen Kraus, Jutta Dierkes, Klaus H Neumann, Wolfgang König.   

Abstract

Increased prevalence of small-sized low-density lipoprotein (LDL) subclass B (diameter < 25.5 nm) possibly is involved in the multifactorial process of cardiovascular disease in patients with end-stage renal disease. Given these epidemiological observations, mechanisms underlying the combined effect of a proinflammatory insult and LDL of different subclasses (subclass A, diameter > 25.5 nm, and subclass B) in a cellular model were investigated. For this, human umbilical vein endothelial cells were preexposed to LDL, then stimulated with tumor necrosis factor-alpha (TNF-alpha). Modulatory effects of LDL phenotypes on the activation of adhesion molecules, monocyte adherence, and transcriptional activity of nuclear factor-kappaB (NF-kappaB) and activator protein-1 (AP-1) were investigated. Our data show that subclass B LDLs were metabolized through nonspecific scavenger receptors and specific LDL-receptor pathways in endothelial cells. Furthermore, LDL subclass B in comparison to subclass A more effectively enhanced monocyte recruitment and adhesive properties of endothelial cells in response to TNF-alpha. These effects appeared not to be mediated by oxidative stress-responsive NF-kappaB because modulation of this transcription factor by LDL was moderate and similar for both LDL phenotypes. Conversely, effects of LDL subclass B were considered to be caused by augmented AP-1 binding activity. In conclusion, the present model provides new clues in atherogenic mechanisms of small-sized LDLs, which sensitize vascular cells to inflammatory signals more effectively than normal-sized LDLs. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11979341     DOI: 10.1053/ajkd.2002.32771

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  4 in total

Review 1.  Vitamin E (Alpha-Tocopherol) Metabolism and Nutrition in Chronic Kidney Disease.

Authors:  Francesco Galli; Mario Bonomini; Desirée Bartolini; Linda Zatini; Gianpaolo Reboldi; Giada Marcantonini; Giorgio Gentile; Vittorio Sirolli; Natalia Di Pietro
Journal:  Antioxidants (Basel)       Date:  2022-05-18

2.  Homocysteinylated albumin promotes increased monocyte-endothelial cell adhesion and up-regulation of MCP1, Hsp60 and ADAM17.

Authors:  Rosanna Capasso; Irene Sambri; Amelia Cimmino; Sofia Salemme; Cinzia Lombardi; Filomena Acanfora; Ersilia Satta; Donald L Puppione; Alessandra F Perna; Diego Ingrosso
Journal:  PLoS One       Date:  2012-02-03       Impact factor: 3.240

3.  Osteopontin deficiency reduces kidney damage from hypercholesterolemia in Apolipoprotein E-deficient mice.

Authors:  Zouwei Pei; Takafumi Okura; Tomoaki Nagao; Daijiro Enomoto; Masayoshi Kukida; Akiko Tanino; Ken-Ichi Miyoshi; Mie Kurata; Jitsuo Higaki
Journal:  Sci Rep       Date:  2016-06-29       Impact factor: 4.379

4.  Impact of Uremic Toxins on Endothelial Dysfunction in Chronic Kidney Disease: A Systematic Review.

Authors:  Eva Harlacher; Julia Wollenhaupt; Constance C F M J Baaten; Heidi Noels
Journal:  Int J Mol Sci       Date:  2022-01-04       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.